Haiyang Xie

19.8k total citations · 4 hit papers
449 papers, 14.9k citations indexed

About

Haiyang Xie is a scholar working on Molecular Biology, Oncology and Surgery. According to data from OpenAlex, Haiyang Xie has authored 449 papers receiving a total of 14.9k indexed citations (citations by other indexed papers that have themselves been cited), including 203 papers in Molecular Biology, 106 papers in Oncology and 99 papers in Surgery. Recurrent topics in Haiyang Xie's work include Organ Transplantation Techniques and Outcomes (60 papers), Liver Disease Diagnosis and Treatment (43 papers) and MicroRNA in disease regulation (38 papers). Haiyang Xie is often cited by papers focused on Organ Transplantation Techniques and Outcomes (60 papers), Liver Disease Diagnosis and Treatment (43 papers) and MicroRNA in disease regulation (38 papers). Haiyang Xie collaborates with scholars based in China, Madagascar and United States. Haiyang Xie's co-authors include Shusen Zheng, Lin Zhou, Xiao Xu, Lin Zhou, Jian Wu, Liming Wu, Feng Zhang, Zhe Yang, Ming-Chun Lai and Xuyong Wei and has published in prestigious journals such as Advanced Materials, Angewandte Chemie International Edition and Nature Communications.

In The Last Decade

Haiyang Xie

439 papers receiving 14.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overexpression of Long Non-coding RNA HOTAIR Predicts Tumor Recurrence in Hepatocellular Carcinoma Patients Following Liver Transplantation

2011 618 citations Ming-Chun Lai, Haiyang Xie et al. profile →
Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma

2018 543 citations Zhigang Ren, Jianwen Jiang et al. profile →
Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation

2011 507 citations Ming-Chun Lai, Haiyang Xie et al. profile →
WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1

2019 479 citations Yunhao Chen, Haiyang Xie et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Haiyang Xie China	58	8.1k	4.6k	3.2k	2.0k	2.0k	449	14.9k
Hongyang Wang China	79	12.2k 1.5×	6.6k 1.4×	4.6k 1.5×	3.4k 1.7×	1.9k 0.9×	486	22.0k
Eli Pikarsky Israel	54	8.8k 1.1×	4.8k 1.0×	5.0k 1.6×	2.8k 1.4×	1.5k 0.8×	135	18.1k
Lin Zhou China	47	4.6k 0.6×	1.9k 0.4×	2.0k 0.6×	1.5k 0.7×	1.5k 0.7×	300	9.2k
Xin Chen China	58	6.6k 0.8×	3.2k 0.7×	2.2k 0.7×	1.1k 0.5×	1.7k 0.8×	382	11.7k
Michele Caraglia Italy	65	7.4k 0.9×	3.2k 0.7×	5.0k 1.6×	1.5k 0.7×	1.4k 0.7×	488	16.0k
Toshiyoshi Fujiwara Japan	58	5.9k 0.7×	2.1k 0.5×	5.1k 1.6×	812 0.4×	2.3k 1.1×	610	13.3k
Xuehao Wang China	53	4.6k 0.6×	2.7k 0.6×	1.7k 0.5×	1.3k 0.6×	1.2k 0.6×	239	9.3k
Xin‐Rong Yang China	48	3.3k 0.4×	2.9k 0.6×	3.5k 1.1×	1.3k 0.6×	1.0k 0.5×	181	9.3k
Ya Cao China	58	7.2k 0.9×	4.7k 1.0×	3.9k 1.2×	1.3k 0.6×	794 0.4×	311	12.6k
Hirofumi Yamamoto Japan	61	6.2k 0.8×	3.5k 0.7×	4.1k 1.3×	683 0.3×	2.4k 1.2×	435	12.6k

Countries citing papers authored by Haiyang Xie

Since Specialization

Citations

This map shows the geographic impact of Haiyang Xie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haiyang Xie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haiyang Xie more than expected).

Fields of papers citing papers by Haiyang Xie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haiyang Xie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haiyang Xie. The network helps show where Haiyang Xie may publish in the future.

Co-authorship network of co-authors of Haiyang Xie

This figure shows the co-authorship network connecting the top 25 collaborators of Haiyang Xie. A scholar is included among the top collaborators of Haiyang Xie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haiyang Xie. Haiyang Xie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xiang, Xiaonan, Kai Wang, Hui Zhang, et al.. (2024). Blocking CX3CR1+ Tumor-Associated Macrophages Enhances the Efficacy of Anti-PD1 Therapy in Hepatocellular Carcinoma. Cancer Immunology Research. 12(11). 1603–1620. 10 indexed citations

Zhang, Liang, Wei Chen, Wei Zhang, et al.. (2023). DBF4 Dependent Kinase Inhibition Suppresses Hepatocellular Carcinoma Progression and Potentiates Anti-Programmed Cell Death-1 Therapy. International Journal of Biological Sciences. 19(11). 3412–3427. 7 indexed citations

Yang, Zhentao, Haiyang Xie, Jianqin Wan, et al.. (2023). A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation. EBioMedicine. 92. 104594–104594. 4 indexed citations

Shi, Xueying, You‐Lin Qiao, Jie Yao, et al.. (2021). Synergistic nanoassemblies constructed from a STAT3 inhibitor and a cabazitaxel prodrug with enhanced cancer chemo-immunotherapy. Materials Today Nano. 17. 100155–100155. 13 indexed citations

Yu, Youyi, Behafarid Ghalandari, Guangxia Shen, et al.. (2021). Poly (N-vinylpyrrolidone) modification mitigates plasma protein corona formation on phosphomolybdate-based nanoparticles. Journal of Nanobiotechnology. 19(1). 8 indexed citations

Chen, Yunhao, Yinan Yao, Haiyang Xie, et al.. (2021). VIRMA contributes to non-small cell lung cancer progression via N6-methyladenosine-dependent DAPK3 post-transcriptional modification. Cancer Letters. 522. 142–154. 41 indexed citations

Zhuo, Jianyong, Di Lu, Jianguo Wang, et al.. (2021). Molecular phenotypes reveal heterogeneous engraftments of patient-derived hepatocellular carcinoma xenografts. Chinese Journal of Cancer Research. 33(4). 470–479. 10 indexed citations

Zhang, Lili, Chao Ge, Fangyu Zhao, et al.. (2020). ZNF143-Mediated H3K9 Trimethylation Upregulates CDC6 by Activating MDIG in Hepatocellular Carcinoma. Cancer Research. 80(12). 2599–2611. 39 indexed citations

Zhuo, Jianyong, Di Lu, Zuyuan Lin, et al.. (2020). C C motif chemokine ligand 16 inhibits the progression of liver cirrhosis via inactivating hepatic stellate cells. Hepatobiliary & pancreatic diseases international. 19(5). 440–448. 13 indexed citations

10.

Xu, Li, Shengjun Xu, Hangxiang Wang, et al.. (2018). Enhancing the Efficacy and Safety of Doxorubicin against Hepatocellular Carcinoma through a Modular Assembly Approach: The Combination of Polymeric Prodrug Design, Nanoparticle Encapsulation, and Cancer Cell-Specific Drug Targeting. ACS Applied Materials & Interfaces. 10(4). 3229–3240. 46 indexed citations

11.

Wang, Hangxiang, Zhongjie Lu, Lijiang Wang, et al.. (2017). New Generation Nanomedicines Constructed from Self-Assembling Small-Molecule Prodrugs Alleviate Cancer Drug Toxicity. Cancer Research. 77(24). 6963–6974. 133 indexed citations

12.

Zhang, Wu, Haiyang Xie, Songming Ding, et al.. (2016). CADM1 regelates the G1/S transition and represses tumorigenicity through the Rb-E2F pathway in hepatocellular carcinoma. Hepatobiliary & pancreatic diseases international. 15(3). 289–296. 21 indexed citations

13.

Lin, Shengzhang, Kangjie Chen, Zhiyuan Xu, et al.. (2013). Prediction of Recurrence and Survival in Hepatocellular Carcinoma Based on Two Cox Models Mainly Determined by FoxP3+ Regulatory T Cells. Cancer Prevention Research. 6(6). 594–602. 41 indexed citations

14.

Ye, Sunyi, et al.. (2013). Interleukin-35: The Future of Hyperimmune-Related Diseases?. Journal of Interferon & Cytokine Research. 33(6). 285–291. 21 indexed citations

15.

Zhang, Lixing, Hefen Sun, Fangyu Zhao, et al.. (2012). BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma. Cancer Research. 72(16). 4276–4285. 82 indexed citations

16.

Sun, Qiang, et al.. (2012). Meta‐analysis: the use of carbon dioxide insufflation vs. room air insufflation for gastrointestinal endoscopy. Alimentary Pharmacology & Therapeutics. 35(10). 1145–1154. 68 indexed citations

17.

Xing, Chunyang, Wuhua Zhou, Songming Ding, et al.. (2012). Reversing Effect of Ring Finger Protein 43 Inhibition on Malignant Phenotypes of human Hepatocellular Carcinoma. Molecular Cancer Therapeutics. 12(1). 94–103. 23 indexed citations

18.

Sun, Junhui, et al.. (2012). In vitro labeling of endothelial progenitor cells isolated from peripheral blood with superparamagnetic iron oxide nanoparticles. Molecular Medicine Reports. 6(2). 282–286. 15 indexed citations

19.

Jiang, Jianwen, et al.. (2011). Enteral supplementation with glycyl-glutamine improves intestinal barrier function after liver transplantation in rats. Hepatobiliary & pancreatic diseases international. 10(4). 380–385. 18 indexed citations

20.

Wu, Jian, Sunyi Ye, Xiaofeng Xu, et al.. (2011). Recipient Outcomes after ABO-Incompatible Liver Transplantation: A Systematic Review and Meta-Analysis. PLoS ONE. 6(1). e16521–e16521. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact